| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
InScape® ER/PR, Quantitative, IHC with Interpretation [16708X]
Test Code16708
CPT Codes
88361 (x2)
Preferred Specimen
Minimum: 1 formalin-fixed, paraffin-embedded tissue block
Minimum Volume
Minimum 6 unstained, positively charged slides
Other Acceptable Specimens
Minimum: 6 unstained, positively charged slides, submitted in IHC Specimen Transport Kit
Instructions
Please include surgical pathology report.
Please note: Per ASCO/CAP guidelines, ER (Estrogen Receptor) and PR (Progesterone Receptor) positivity requires at least 1% of tumor cells to show positive nuclear staining of any intensity.
A negative result for ER and PR will be reported if < 1% of tumor cells show staining.
Please note: Per ASCO/CAP guidelines, ER (Estrogen Receptor) and PR (Progesterone Receptor) positivity requires at least 1% of tumor cells to show positive nuclear staining of any intensity.
A negative result for ER and PR will be reported if < 1% of tumor cells show staining.
Transport Container
IHC Specimen Transport Kit
Transport Temperature
Room temperature
Specimen Stability
Room temperature: Indefinitely
Refrigerated: Indefinitely
Frozen: Unacceptable
Refrigerated: Indefinitely
Frozen: Unacceptable
Methodology
Immunohistochemistry (IHC)
Setup Schedule
Set up: Mon-Fri; Report available: 1 day
Reference Range
See Medical Report
Clinical Significance
Breast cancer is a heterogeneous disease and there is a continual drive to identify markers that will aid in predicting prognosis and response to therapy. Estrogen receptor (ER) is probably the most powerful predictive marker in breast cancer management, both in determining prognosis and in predicting response to hormone therapies. Progesterone receptor (PR) is an estrogen-regulated gene and its expression is therefore thought to indicate a functioning ER pathway, although its value is less well established.
Performing Laboratory
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly, VA 20153
